scispace - formally typeset
S

Steven P. Gygi

Researcher at Harvard University

Publications -  778
Citations -  147003

Steven P. Gygi is an academic researcher from Harvard University. The author has contributed to research in topics: Proteome & Phosphorylation. The author has an hindex of 172, co-authored 704 publications receiving 129173 citations. Previous affiliations of Steven P. Gygi include University of Rochester Medical Center & Cell Signaling Technology.

Papers
More filters
Journal ArticleDOI

PIASy-dependent SUMOylation regulates DNA topoisomerase IIα activity

TL;DR: SUMOylation of TopoIIα inhibits its decatenation activity, preventing resolution of tangled DNA at centromeres before anaphase onset.
Journal ArticleDOI

ACP acylation is an acetyl-CoA-dependent modification required for electron transport chain assembly

TL;DR: It is demonstrated that the acylated form of ACP is an acetyl-CoA-dependent allosteric activator of the LYR protein family used to stimulate ETC biogenesis and could provide an elegant mechanism for coordinating the assembly of ETC complexes with one another and with substrate availability.
Journal ArticleDOI

A Temporal Proteomic Map of Epstein-Barr Virus Lytic Replication in B Cells.

TL;DR: EBV-induced remodeling of cell cycle, innate and adaptive immune pathways, including upregulation of the complement cascade and proteasomal degradation of the B cell receptor complex, conserved between EBV types I and II are revealed.
Journal ArticleDOI

The Proteasome Distinguishes between Heterotypic and Homotypic Lysine-11-Linked Polyubiquitin Chains

TL;DR: It is demonstrated that pure homotypic lysine-11-linked chains do not bind strongly to the mammalian proteasome, with implications for the recognition and diverse biological functions of mixed ubiquitin chains.
Journal ArticleDOI

Trim32 reduces PI3K-Akt-FoxO signaling in muscle atrophy by promoting plakoglobin-PI3K dissociation.

TL;DR: By promoting dissociation of the desmosomal component plakoglobin fromPI3K, the ubiquitin ligase Trim32 reduces PI3K–Akt–FoxO signaling in normal and atrophying muscle, potentially contributing to insulin resistance and catabolic disorders.